Abstract: A method and kit are provided for measuring and monitoring a combined effect of an anticoagulant drug on coagulation factors II and X in a patient taking the anticoagulant drug. The method includes adding one or more coagulation reagents with the factor VII to a test sample and determining blood clotability of the test sample by measuring an influence of factors II and X.
Type:
Grant
Filed:
August 1, 2025
Date of Patent:
July 14, 2026
Assignee:
FIIX DIAGNOSTICS
Inventors:
Pall T. Onundarson, Brynja R. Gudmundsdottir
Abstract: A method and kit are provided for monitoring anticoagulant therapy based on measuring the simultaneous influence of factors II and X only, in a test sample (i.e., test plasma or whole blood) of an anticoagulated patient, by creating a corrected sample that circumvents measuring also the influence of fibrinogen, factor V, and factor VII on the clotting process in the corrected sample. One or more coagulation reagents that activate factor VII or factor X, but not factor IX, are added to the corrected sample, and the blood clotting ability of the corrected plasma sample is subsequently determined by measuring blood clotting time. Alternatively, a reagent plasma with added factor VII is mixed into the reagent activator, such as thromboplastin, that is subsequently added to a sample of test plasma or whole blood to correct the test sample and measure the simultaneous influence of only factors II and X.
Type:
Grant
Filed:
September 3, 2024
Date of Patent:
September 2, 2025
Assignee:
FIIX DIAGNOSTICS
Inventors:
Pall T. Onundarson, Brynja R. Gudmundsdottir